Here’s what you’ll expect from Abbvie’s next revenue report

Based in North Chicago, Illinois, Abbvie Inc. (ABBV) discovers, develops, manufactures and sells medicines from around the world. With a market capitalization of $334.3 billion, the company discovers and develops medicines and treatments that solve health problems across immunology, oncology, aesthetics, neuroscience and eye care. The drug giant is expected to announce its second quarter of 2025 before the market opens on Thursday, July 31st.

Ahead of the event, analysts expect ABBV to report earnings of $3.24 per share on a diluted basis. The company has consistently surpassed Wall Street EPS estimates in its past four quarterly reports.

Over the course of a year, analysts expect ABBV to report an EPS of $12.28, up 21.3% from $10.12 in 2024. That EPS is expected to rise 14.5% in fiscal year 2026.

ABBV shares outweighed its S&P 500 Index ($SPX) 13.4% profit over the past 52 weeks, up 15.5% over this period. Similarly, the Healthcare Select Sector SPDR Fund (XLV) exceeded 5.4% over the same time frame.

ABBV’s outperformance is driven by the success of New Immunology Medicines Skyrizi and Rinvoq, which offset the loss of Humira’s exclusiveness. Strategic acquisitions, including Capstan Therapeutics and Immunogen, strengthen the pipeline of immunology, oncology and neurosciences, positioning the company for robust revenue growth from 2025 onwards. Furthermore, Abbvie’s focus on oncology has attracted attention with new products such as Elahere and Epkinly and new drug invasion into the obesity market.

On April 25, ABBV shares closed more than 3% after reporting first quarter results. The $2.46 adjusted EPS exceeded Wall Street’s expectations at $2.39. The company had revenues of $13.3 billion, while Wall Street forecast was $12.9 billion. ABBV expects EPS in the annual adjusted EPS ranges from $12.09 to $12.29.

Analyst consensus opinions on ABBV stocks are moderately bullish, with an overall “medium buy” rating. Of the 27 analysts covering stocks, 14 advise on a “strong buy” rating, two suggest “medium buy” and 11 give “hold.” ABBV’s average analyst price target is $208.88, indicating a potential upside of 10.4% from current levels.

On the date of publication, Neha Panjwani had no position (directly or indirectly) in any of the securities mentioned in this article. All information and data in this article is for informational purposes only. This article was originally published barchart.com